Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis

Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis. Show citation: Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet . 2026;407(10540):1712-1725. doi:…